Compare RAVE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | OTLK |
|---|---|---|
| Founded | 1958 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 38.7M |
| IPO Year | 1995 | 2016 |
| Metric | RAVE | OTLK |
|---|---|---|
| Price | $2.65 | $0.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 21.1K | ★ 1.1M |
| Earning Date | 05-07-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 55.91 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $15,120,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,726.70 |
| Revenue Next Year | N/A | $80.34 |
| P/E Ratio | $29.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $0.29 |
| 52 Week High | $3.75 | $3.39 |
| Indicator | RAVE | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 34.70 |
| Support Level | $2.34 | N/A |
| Resistance Level | $3.21 | $0.46 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 48.65 | 30.41 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.